Ligand Pharmaceuticals (LGND) Institutional Ownership Tracker (Q2 2026)

LGND ranks #1465 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

LGND is a top-conviction position for Villere St Denis J & Co LLC — at 5.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in LGND belongs to BlackRock, Inc., but the position matters far more to Villere St Denis J & Co LLC, who has 5.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its LGND position for two straight quarters, increasing it by $424.3M to reach $980.2M today.

Jacobs Levy Equity Management, Inc has trimmed its LGND position for two straight quarters, cutting it by $20.2M while still holding $3.8M.

LGND is down 1.4% today, but institutions show net buying of $2.2B this quarter — a divergence between today's price move and the underlying institutional flow.

LGND posted net income of $197.2M over the trailing twelve months, and currently trades at a P/E of 28.9.

• Profitable — net income of $197.2M over the trailing twelve months
• Revenue grew 54.9% year over year
• Net income improved year over year, from -$75.9M to $197.2M
• Generated $49.4M in positive operating cash flow
• Current ratio of 22.23x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.53x equity — within a conventional range